In R&D, small biotechs hold their own against big pharma
A new report from Iqvia found that small biotechs were responsible for nearly two-thirds of the new drugs approved by the FDA last year, rivaling big pharma!
With smaller R&D budgets than large drugmakers, these companies developed 38 of the 59 therapies approved in 2018 and accounted for almost half of the regulatory applications leading to those approvals. Iqvia notes that these numbers suggest emerging biotechs are retaining control of the drugs they develop for longer, holding off on the licensing or partnering deals.
